IVD compliance policy guide should deem "experimental use" products unregulated -- JCIM petition.
This article was originally published in The Gray Sheet
Executive Summary
IVD COMPLIANCE POLICY GUIDE: "EXPERIMENTAL USE ONLY" PRODUCTS should be recognized as an unregulated category in the FDA's CPG on commercialization of unapproved in vitro diagnostics, the Joint Council of Immunohistochemical Manufacturers states in a May 14 petition submitted to FDA. "The CPG's failure to acknowledge that this category of products exists and that they should be unregulated has created confusion among the research community and raised the specter of regulating pure research materials," JCIM claims.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.